QQ客服 官方微博 反馈留言

	Simvastatin inhibits tumor angiogenesis in HER2-overexpressing human colorectal cancer
	Li Gang[1]; Zheng Junhua[2]; Xu Bin[3]; Ling Jie[4]; Qiu Wei[5]; Wang Yongbing[6]
刊名	Biomedicine & pharmacotherapy
	2017
卷号	85页码:418-424
关键词	Anti-angiogenesis Colorectal cancer HER2 Simvastatin VEGF
ISSN号	1950-6007
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2224059
专题	上海大学
作者单位	1.[1]Department of General Surgery, Shanghai Pudong New area People Hospital affiliated to Shanghai University of Medicine & Health Sciences, Shanghai 201200, China. 2.[2]Department of General Surgery, Shanghai Pudong New area People Hospital affiliated to Shanghai University of Medicine & Health Sciences, Shanghai 201200, China. 3.[3]Department of General Surgery, Shanghai Pudong New area People Hospital affiliated to Shanghai University of Medicine & Health Sciences, Shanghai 201200, China. 4.[4]Department of General Surgery, Shanghai Pudong New area People Hospital affiliated to Shanghai University of Medicine & Health Sciences, Shanghai 201200, China. 5.[5]Department of General Surgery, Shanghai Pudong New area People Hospital affiliated to Shanghai University of Medicine & Health Sciences, Shanghai 201200, China. 6.[6]Department of General Surgery, Shanghai Pudong New area People Hospital affiliated to Shanghai University of Medicine & Health Sciences, Shanghai 201200, China. Electronic address: wybpd@sina.com.
推荐引用方式 GB/T 7714	Li Gang[1],Zheng Junhua[2],Xu Bin[3],et al. Simvastatin inhibits tumor angiogenesis in HER2-overexpressing human colorectal cancer[J]. Biomedicine & pharmacotherapy,2017,85:418-424.
APA	Li Gang[1],Zheng Junhua[2],Xu Bin[3],Ling Jie[4],Qiu Wei[5],&Wang Yongbing[6].(2017).Simvastatin inhibits tumor angiogenesis in HER2-overexpressing human colorectal cancer.Biomedicine & pharmacotherapy,85,418-424.
MLA	Li Gang[1],et al."Simvastatin inhibits tumor angiogenesis in HER2-overexpressing human colorectal cancer".Biomedicine & pharmacotherapy 85(2017):418-424.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。